Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol "FAVOR"

Active, not recruiting

Phase 4 Results N/A

Trial Description

Confirm central blood pressure reduction effect of Fimasartan, Valsartan and Atenolol and compare correlation with the measured peripheral (central blood pressure, pulse wave velocity, and flow-mediated dilation) and cerebral blood flow factors (transcranial doppler findings, cerebral blood flow volume) in acute ischemic stroke patients with hypertension.



  • Atenolol (Tenormin)Drug
    Other Names: tenormin
    ARM 1: Kind: Experimental
    Label: Atenolol
    Description: atenolol 50mg, 1 tablet by mouth, every day beta-blocker
  • Valsartan (Diovan,)Drug
    ARM 1: Kind: Experimental
    Label: Valsartan
    Description: valsartan 80mg, 1 tablet by mouth, every day angiotensin II receptor antagonists
  • Fimasartan Drug
    Other Names: kanarb
    ARM 1: Kind: Experimental
    Label: Fimasartan
    Description: fimasartan potassium 60mg, 1 tablet by mouth, every day Angiotensin ll receptor blocker

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment


Type Measure Time Frame Safety Issue
Primary Central Blood pressure control 12 weeks No
Secondary Blood pressure at the brachial artery 12 weeks No
Secondary Brachial-ankle pulse wave velocity (ba-PWV) 12 weeks No
Secondary Flow-mediated dilation (FMD) 12 weeks No
Secondary Pulsatile index (PI) 12 weeks No
Secondary Cerebral blood flow (CBF) volume 12 weeks No
Secondary Adverse Events 12 weeks Yes